Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.84 – $3.11
Volume20,607
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for LIMN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for LIMN.
Recent news
Company coverage with links to the original publishers.
Liminatus Pharma (LIMN) received a delisting notice from Nasdaq on May 20, 2026, after failing to meet minimum market value requirements ($50M MVLS and $15M MVPHS) within the 180-day compliance period. The company intends to appeal the decision before the Nasdaq Hearings Panel by May 27, 2026, which will stay any suspension pending the hearing.
Liminatus Pharma announced a definitive merger agreement with InnocsAI LLC, a biotechnology company specializing in CAR-T and antibody-based oncology therapies. Under the agreement, InnocsAI members will receive 1.6 billion shares of Liminatus common stock at $0.20 per share, valuing the transaction at approximately $320 million. The merger aims to expand Liminatus' oncology pipeline with advanced cell therapy assets including IBC101 (bivalent CAR-T for B-cell malignancies) and INC101 (dual-antigen CAR-T for solid tumors), pending shareholder and regulatory approvals.
Liminatus Pharma (LIMN) shares surged 79.34% to $0.34 in after-hours trading following the announcement of a definitive merger agreement with InnocsAI LLC. The deal brings a clinical-stage oncology portfolio including CAR-T and solid tumor programs. However, the stock has declined 96.95% over the past 12 months and trades near its 52-week low, with technical indicators showing negative price trends across all timeframes.
Liminatus Pharma (NASDAQ: LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of a public offering of 13.8 million shares and warrants at $0.29 per share, expected to raise approximately $4.0 million in gross proceeds. The offering is expected to close on February 18, 2026, with net proceeds to be used for working capital and advancement of the company's CD47-blockade therapeutic programs.
Liminatus Pharma, a clinical-stage immuno-oncology company, has entered a Memorandum of Understanding with Capital Trust Group for a $30 million equity investment to support its research and development of advanced immunotherapy assets.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.